Full-Time
Senior Scientist
Chemical Development
Alumis
201-500 employees
Develops precision therapies for immune diseases
No salary listed
San Bruno, CA, USA
In Person
Willing to travel up to 25% domestically and internationally.
Master's, PhD
 Biology & Biotech (1) |
|---|
Get referred to Alumis
See people who can refer or advise you
- PhD in Organic Chemistry, Chemical Engineering, or related field
- Knowledge of cGMP, ICH, and regulatory requirements
- Drive CDMO activities for late-stage drug substance development and manufacturing, including tech transfer, scale-up, process development, and optimization.
- Provide technical guidance and oversight (both internally and externally) to drive the phase appropriate drug substance development.
- Serve as subject matter expert in chemical development and help drive best practices and technical advancements.
- Review and approve cGMP documents, including batch records, change controls, deviations, specifications, validation master plan, validation protocols/reports.
- Draft the CMC sections of regulatory filings, including IND/IMPDs and NDA/MAAs
- Document development activities as source reports for regulatory filings.
- Work effectively with the cross-functional CMC team to ensure timely delivery of drug substance throughout the full drug lifecycle.
- Implement best practices and drive continuous improvements in the drug substance development process through technology innovation and problem solving.
- Proactively identify risks and communicate effectively with functional teams across all levels of the organization.
- Work in the lab to solve process chemistry issues (20% - 40%).
- Knowledge of cGMP, ICH, and regulatory requirements
- PhD with minimum of 5 years of experience in small molecule drug substance development, including management of external vendors/CDMOs or MS with minimum of 8 years of experience is desirable
- Experience with late-stage drug substance technical transfer
- Experience with control strategy development and capable of utilizing Quality by Design principles to develop commercially viable manufacturing processes
- Highly proficient oral and written communication abilities
- Strong presentation skills
- Excellent collaboration, problem-solving, and organizational skills
- Comfortable in a fast-paced small company environment
- Ability to travel domestically and internationally (including Asian countries) up to 25% of the time to support ongoing manufacturing activities
- Bilingual in Japanese/English and able to act as a technical translator for written and verbal communication and technical documents strongly preferred
Alumis develops precision therapies for immune-mediated diseases. By using genetic and disease biology insights, it designs targeted treatments and selects the right targets, molecules, indications, patient groups, endpoints, and possible combinations to optimize outcomes. The company differentiates itself by aligning therapy development with genetic and immunologic understanding to match medicines to the patients who will benefit most. Its goal is to improve clinical outcomes by bringing precision therapies to market and pursuing partnerships or licensing to support development and commercialization.
Company Size
201-500
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2021
Get referred to Alumis
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 13, 2026 results kept the envudeucitinib psoriasis NDA on track for Q4 2026.
- Deep Track Capital bought 6.77 million shares in Q1 2026, validating the pipeline.
- June 30, 2026 cash reached $502.3 million, funding operations into Q4 2027.
What critics are saying
- Q2 2026 revenue fell to $1.7 million while net loss widened to $142.2 million.
- Lonigutamab impairment and strategic review signal damaged asset value after the ACELYRIN merger.
- Single-asset dependence on envudeucitinib makes a Q4 2026 NDA failure existential.
What makes Alumis unique
- Envudeucitinib combines TYK2 inhibition with late-stage psoriasis and lupus programs in 2026.
- Alumis pairs oral immunology assets with CNS-penetrant A-005 for Parkinson's and multiple sclerosis.
- The 2025 ACELYRIN merger created a broader immune-mediated diseases platform under one management team.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Unlimited Paid Time Off
Remote Work Options
Commuter Benefits
Phone/Internet Stipend
Gym Membership
Stock Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%Alumis reported second quarter 2026 financial results, highlighting that 54% of patients achieved complete skin clearance in its ONWARD3 trial for envudeucitinib in plaque psoriasis after 48 weeks. The company remains on track to submit a New Drug Application to the FDA for the treatment in Q4 2026. The biopharmaceutical firm anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in systemic lupus erythematosus in Q3 2026. Alumis plans to initiate a Phase 2 biomarker trial for A-005, its CNS-penetrant TYK2 inhibitor, in Parkinson's disease patients in the first half of 2027. As of 30 June 2026, Alumis held cash, cash equivalents and marketable securities of $502.3 million. Research and development expenses decreased to $85.3 million from $108.8 million year-over-year. Net loss was $142.2 million for the quarter.
- **Stake Acquisition**: Deep Track Capital disclosed a purchase of 6,772,595 shares of Alumis in Q1 2026, valued at approximately $169.31 million, in...
Deep Track Capital acquired 6,772,595 shares of Alumis (NASDAQ:ALMS) during the first quarter of 2026, an estimated $169.31 million investment based on quarterly average pricing, according to a 15 May SEC filing. The biotechnology company develops therapies for autoimmune and neuroinflammatory diseases. Its lead candidate, envudeucitinib, showed strong Phase 3 psoriasis results with PASI 90 response rates of 68.0% and 62.1% by Week 24. Alumis plans to submit an NDA in the fourth quarter, whilst pivotal Phase 2b lupus data are expected in the third quarter. Alumis shares were trading at $22.02, up 355% over the past year, outperforming the S&P 500's 28% gain. The company held $569.5 million in cash as of quarter-end, sufficient to fund operations into the fourth quarter of 2027.
Omega Fund Management sold 411,968 shares of Alumis in the first quarter, reducing its stake to 241,255 shares, according to an SEC filing. The transaction was valued at approximately $10.3 million based on quarterly average pricing. Despite the sale, Alumis remains a meaningful holding for Omega at 3.3% of assets under management. The move appears to be profit-taking following Alumis shares' 327% gain over the past year, significantly outperforming the S&P 500's roughly 25% increase. Alumis, a clinical-stage biotechnology company developing therapies for autoimmune diseases, recently reported positive late-stage psoriasis data for its lead TYK2 inhibitor candidate. The company plans an FDA submission in the fourth quarter and ended the quarter with $569.5 million in cash, sufficient to fund operations into late 2027.
ACT Capital Management has acquired 174,250 shares of Alumis for approximately $4.36 million, establishing a new position representing 3.02% of its assets under management, according to an SEC filing dated 8 May 2026. The clinical-stage biotechnology company focuses on autoimmune and neuroinflammatory disorders, with lead candidates targeting TYK2 inhibition. Alumis shares have surged 350% over the past year to $23.76, driven by positive Phase 3 data showing 65% of patients achieving PASI 90 skin clearance in plaque psoriasis trials. The company plans to submit a new drug application in the second half of 2026 and expects pivotal Phase 2b lupus data in the third quarter. Alumis raised $345 million in January and held $308.5 million in cash at year-end, despite posting a $243 million net loss.